ObjectiveTo summarize the influence and mechanism of visceral fat on the treatment and prognosis of gastric cancer patients.MethodLiteratures on the correlation and mechanism between visceral fat and treatment and prognosis of gastric cancer were collected and reviewed.ResultsHigh visceral fat may promote the incidence and progress of gastric cancer, and increase the incidence of complication of radical gastrectomy, including surgical site infection, pancreatic fistula, etc., as well as prolong the length of hospital stay. Reducing patients’ visceral fat level before operation could reduce the incidence of surgical complication. However, the persistent decrease of visceral fat level after operation may indicate poor prognosis. The effect of visceral fat on gastric cancer and its treatment was mainly due to the local chronic inflammation caused by excessive visceral fat tissue, the change of adipocytokine secretion, insulin resistance, and other mechanisms.ConclusionWe need to use visceral fat and other indicators to evaluate gastric cancer patients’ weight and body composition, in order to better guide the treatment and prognosis evaluation of gastric cancer.
Objective To understand the latest research progress of chemotherapy, targeted therapy and immunotherapy drugs in the treatment of metastatic colorectal cancer. Method The literature on the efficacy of different treatment drugs for metastatic colorectal cancer in recent years both domestically and internationally was retrieved and reviewed. Results There had been many clinical research progress in the treatment of metastatic colorectal cancer, new drugs had emerged, targeted drugs were particularly prominent, and more trials of therapeutic drugs and drug combination treatment regimens were also being carried out. Different treatment methods were applied to patients according to the mutation status of RAS/RAF and the expression of mismatch repair protein, the survival benefit varied greatly. Conclusion Precision medicine is becoming increasingly important, screening patients to choose appropriate treatment modality can further improve survival benefit.
ObjectiveTo recognize the latest research progress of immunotherapy for advanced gastric cancer (AGC). MethodThe domestic and international literature on immunotherapy for AGC in recent years were retrieved and reviewed. ResultsThe immunotherapy for AGC mainly focused on immune checkpoint inhibitors (ICIs), cellular immunity, and antitumor vaccines. The most immunotherapy researched was ICIs, especially for programmed death protein-1 / programmed death protein ligand 1, cytotoxic T lymphocyte associated antigen 4, and lymphocyte activating gene 3. The cellular immunotherapy and tumor vaccine therapy were less relatively. Although immunotherapy alone did not have a particularly good effect, its therapeutic effect was not inferior to that of chemotherapy alone and the incidence of adverse reactions was lower. Moreover, most studies had concluded that the use of immunotherapy in combination with other therapy had shown a good clinical efficacy, especially in combination with anti-human epidermal growth factor receptor 2 antibody, and chimeric antigen receptor T cells targeting Claudin 18.2 site had promising results in the AGC. ConclusionsWith the development of immunotherapy research, the strategies of immunotherapy for AGC are also constantly improving. Precision medicine is important in the process of immunotherapy. Targeted screening suitable patients and adopting precise treatment can further benefit the survival of patients with AGC.